BACKGROUND: Although invasive pneumococcal pneumonia remains responsible for a significant number of child hospitalizations, specific data on hospital resource utilization and related costs are limited. OBJECTIVES: To assess the cost of hospitalizing children with invasive pneumococcal pneumonia and identify the cost determinants of the disease. PATIENTS AND METHODS: Economic evaluation based on an observational study of all children <18 years of age with culture-proved invasive pneumococcal pneumonia admitted to a referral hospital in Barcelona (Spain) during the period January 2001-December 2011. Analysis included demographic, microbiological, epidemiological and clinical variables. RESULTS: A total of 135 children were included in the study (median age 3.3 years). PCV13 serotypes were detected in 132 (97.8%) cases. Median hospital cost was €4533 (€4078-5435, 95% CI). Median length of stay was 11.0 days (10.6-13.0 days, 95% CI). Variables significantly associated with increased cost in the multivariate analysis were complicated pneumonia (≥2 and 1 complication) versus non-complicated pneumonia (€4919 and €2822 vs. €1399), performance of surgery versus no surgery (€4849 vs. €1435), intensive care versus no intensive care (€6488 vs. €3862) and identification of non-PCV7 serotypes versus PCV7 serotypes (€4656 vs. €1470). CONCLUSION: Invasive pneumococcal pneumonia in children makes substantial demands on hospital health care and financial resources that could be mitigated with universal PCV13 childhood immunization programmes and early management of complications.
BACKGROUND: Although invasive pneumococcal pneumonia remains responsible for a significant number of child hospitalizations, specific data on hospital resource utilization and related costs are limited. OBJECTIVES: To assess the cost of hospitalizing children with invasive pneumococcal pneumonia and identify the cost determinants of the disease. PATIENTS AND METHODS: Economic evaluation based on an observational study of all children <18 years of age with culture-proved invasive pneumococcal pneumonia admitted to a referral hospital in Barcelona (Spain) during the period January 2001-December 2011. Analysis included demographic, microbiological, epidemiological and clinical variables. RESULTS: A total of 135 children were included in the study (median age 3.3 years). PCV13 serotypes were detected in 132 (97.8%) cases. Median hospital cost was €4533 (€4078-5435, 95% CI). Median length of stay was 11.0 days (10.6-13.0 days, 95% CI). Variables significantly associated with increased cost in the multivariate analysis were complicated pneumonia (≥2 and 1 complication) versus non-complicated pneumonia (€4919 and €2822 vs. €1399), performance of surgery versus no surgery (€4849 vs. €1435), intensive care versus no intensive care (€6488 vs. €3862) and identification of non-PCV7 serotypes versus PCV7 serotypes (€4656 vs. €1470). CONCLUSION:Invasive pneumococcal pneumonia in children makes substantial demands on hospital health care and financial resources that could be mitigated with universal PCV13 childhood immunization programmes and early management of complications.
Authors: Shanshan Zhang; Peter M Sammon; Isobel King; Ana Lucia Andrade; Cristiana M Toscano; Sheila N Araujo; Anushua Sinha; Shabir A Madhi; Gulam Khandaker; Jiehui Kevin Yin; Robert Booy; Tanvir M Huda; Qazi S Rahman; Shams El Arifeen; Angela Gentile; Norberto Giglio; Mejbah U Bhuiyan; Katharine Sturm-Ramirez; Bradford D Gessner; Mardiati Nadjib; Phyllis J Carosone-Link; Eric Af Simões; Jason A Child; Imran Ahmed; Zulfiqar A Bhutta; Sajid B Soofi; Rumana J Khan; Harry Campbell; Harish Nair Journal: J Glob Health Date: 2016-06 Impact factor: 4.413